CDH2 and prostate carcinoma: Similarly in prostate cancer, markers of a mesenchymal phenotype including CDH2, osteoblast-cadherin (CDH11), and WAP-type four disulfide core/ps20 (WFDC-1) proteins are upregulated correlating with cellular motility, Skp1-cullin 1-F-box (SCF) E3 ligase complex/ubiquitin/proteasome pathway activity and loss of typical prostatic glandular architecture [37,38,39,40,41].